Investments
261Portfolio Exits
97Funds
6Partners & Customers
10Expert Collections containing Deerfield Management
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Deerfield Management in 2 Expert Collections, including Synthetic Biology.
Synthetic Biology
382 items
CB Insights Healthcare Smart Money Investors - 2020
25 items
Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.
Research containing Deerfield Management
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Deerfield Management in 4 CB Insights research briefs, most recently on Feb 16, 2021.

Latest Deerfield Management News
May 16, 2022
Illumina, Deerfield Ink Drug Development Deal On May 5, the San Diego DNA sequencing giant announced a partnership with New York-based healthcare investment management firm Deerfield Management to apply a genetic-led approach to develop novel therapies for diseases with unmet medical needs. Alex AravanisCTOIllumina The five-year partnership will leverage Illumina’s genomic tools and data with Deerfield’s operational and financial expertise managing $14 billion in AUM (assets under management) across 200 public and private portfolio companies – many in the therapeutic space – to guide successful candidates through clinical development. Under the terms of the partnership with Deerfield, Illumina will provide a DNA-driven target discovery platform alongside its AI-powered genome interpretation software while Deerfield will provide expertise in translational science and help guide new drug candidates through preclinical testing. “This partnership serves as a new company (NewCo) creation engine where Illumina and Deerfield will jointly decide whether to progress validated targets into pre-clinical development, at which point a NewCo will be formed,” said Illumina CTO Alex Aravanis. “It is a co-ownership model that gives both Illumina and Deerfield equity in the NewCo, generating drug target assets with long-term optionality that includes royalties if a drug reaches the market,” Aravanis added. “The partnership is openly structured where both parties are aligned in near and long-term success.” Joydeep GoswamiChief Strategy and Corporate Development OfficerIllumina Illumina Chief Strategy and Corporate Development Officer Joydeep Goswami said this is due to “gaps in the biological understanding of the complex nature of many diseases” and a drug discovery process that is “difficult, expensive and slow.” Goswami pointed out that Deerfield VP of Genetics and Genomics Matt Nelson’s paper published in “Nature” supported using genetic data to select the best targets and indications in discovery and can improve success rates, speed to market, and cost in the development of new drugs. “Our partnership will work to create efficiencies across the drug development process, through data and AI, and change how we can bring novel therapeutics to market, overcoming the hurdles traditional models have failed to overcome,” Aravanis added. “Leveraging Illumina’s sequencing platform to grow data assets at massive scale, our best-in-class AI tools to interpret the genome and Deerfield’s deep scientific and investment expertise in the therapeutics space, we believe this is a unique engine to industrialize drug development.” Illumina and Deerfield plan to identify therapeutic targets using Illumina’s genetically driven target discovery platform built with Illumina Connected Analytics and AI-driven genome interpretation solutions. James FlynnManaging PartnerDeerfield Management “Illumina is an innovative global leader in genomics,” said Deerfield Management Managing Partner James Flynn. “Together, with Deerfield’s expertise in translational research, the partnership will fuel advancements from idea to clinic more efficiently with the goal of treating some of the world’s most life-threatening diseases.”
Deerfield Management Investments
261 Investments
Deerfield Management has made 261 investments. Their latest investment was in Apertura Gene Therapy as part of their Series A on April 4, 2022.
Deerfield Management Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
4/26/2022 | Series A | Apertura Gene Therapy | $67M | Yes | 2 | |
4/12/2022 | Series A | Aurion Biotech | $120M | Yes | 6 | |
2/24/2022 | Series A - II | Vibliome Therapeutics | $22M | No | 1 | |
2/23/2022 | Series E | |||||
2/3/2022 | Series B |
Date | 4/26/2022 | 4/12/2022 | 2/24/2022 | 2/23/2022 | 2/3/2022 |
---|---|---|---|---|---|
Round | Series A | Series A | Series A - II | Series E | Series B |
Company | Apertura Gene Therapy | Aurion Biotech | Vibliome Therapeutics | ||
Amount | $67M | $120M | $22M | ||
New? | Yes | Yes | No | ||
Co-Investors | |||||
Sources | 2 | 6 | 1 |
Deerfield Management Portfolio Exits
97 Portfolio Exits
Deerfield Management has 97 portfolio exits. Their latest portfolio exit was PepGen on May 06, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
5/6/2022 | IPO | 1 | |||
4/29/2022 | IPO | 5 | |||
12/13/2021 | Acq - P2P | 5 | |||
Deerfield Management Acquisitions
2 Acquisitions
Deerfield Management acquired 2 companies. Their latest acquisition was Endologix on October 01, 2020.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
10/1/2020 | Debt | $177.5M | Take Private | 3 | ||
10/2/2017 |
Date | 10/1/2020 | 10/2/2017 |
---|---|---|
Investment Stage | Debt | |
Companies | ||
Valuation | ||
Total Funding | $177.5M | |
Note | Take Private | |
Sources | 3 |
Deerfield Management Fund History
6 Fund Histories
Deerfield Management has 6 funds, including Deerfield Healthcare Venture Fund.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
4/6/2020 | Deerfield Healthcare Venture Fund | $840M | 1 | ||
11/25/2016 | Deerfield Private Design Fund IV | ||||
7/28/2015 | Deerfield Healthcare Innovations Fund | ||||
4/7/2014 | Deerfield Private Design Fund III | ||||
Deerfield Healthcare Innovations Fund II |
Closing Date | 4/6/2020 | 11/25/2016 | 7/28/2015 | 4/7/2014 | |
---|---|---|---|---|---|
Fund | Deerfield Healthcare Venture Fund | Deerfield Private Design Fund IV | Deerfield Healthcare Innovations Fund | Deerfield Private Design Fund III | Deerfield Healthcare Innovations Fund II |
Fund Type | |||||
Status | |||||
Amount | $840M | ||||
Sources | 1 |
Deerfield Management Partners & Customers
10 Partners and customers
Deerfield Management has 10 strategic partners and customers. Deerfield Management recently partnered with Illumina on May 5, 2022.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
5/5/2022 | Partner | United States | 09:15 EDT Illumina and Deerfield Management partner to accelerate drug development Illumina , Inc. and Deerfield Management today announced a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies for diseases with unmet medical needs . | 3 | |
1/18/2022 | Partner | United States | Deerfield and Stanford University Create the Porter Alliance for Innovative Medicines SAN FRANCISCO & NEW YORK -- -- Stanford University School of Medicine and Deerfield Management , a healthcare investment firm , have collaborated to create Porter Alliance for Innovative Medicines to accelerate translational research into clinical therapeutics . | 1 | |
11/24/2020 | Partner | India | Contract Pharma Staff11.24.20. Syngene And 3DC Sign 5-year Collaboration - Contract Pharma Syngene International and Deerfield Discovery and Development Corporation , the drug discovery and development subsidiary of Deerfield Management Company , have signed an agreement to collaborate to advance therapeutic discovery projects , from target validation through to pharmacological proof of concept and preclinical evaluation . | 1 | |
11/19/2020 | Partner | ||||
6/5/2019 | Partner |
Date | 5/5/2022 | 1/18/2022 | 11/24/2020 | 11/19/2020 | 6/5/2019 |
---|---|---|---|---|---|
Type | Partner | Partner | Partner | Partner | Partner |
Business Partner | |||||
Country | United States | United States | India | ||
News Snippet | 09:15 EDT Illumina and Deerfield Management partner to accelerate drug development Illumina , Inc. and Deerfield Management today announced a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies for diseases with unmet medical needs . | Deerfield and Stanford University Create the Porter Alliance for Innovative Medicines SAN FRANCISCO & NEW YORK -- -- Stanford University School of Medicine and Deerfield Management , a healthcare investment firm , have collaborated to create Porter Alliance for Innovative Medicines to accelerate translational research into clinical therapeutics . | Contract Pharma Staff11.24.20. Syngene And 3DC Sign 5-year Collaboration - Contract Pharma Syngene International and Deerfield Discovery and Development Corporation , the drug discovery and development subsidiary of Deerfield Management Company , have signed an agreement to collaborate to advance therapeutic discovery projects , from target validation through to pharmacological proof of concept and preclinical evaluation . | ||
Sources | 3 | 1 | 1 |
Deerfield Management Team
10 Team Members
Deerfield Management has 10 team members, including current Chief Executive Officer, Michael A Foley.
Name | Work History | Title | Status |
---|---|---|---|
Michael A Foley | Chief Executive Officer | Current | |
Luke Knecht | Chief Operating Officer | Current | |
Joseph Pearlberg | Infinity Pharmaceuticals, Sanofi, Massachusetts General Hospital, Harvard Medical School, and Harvard University | Senior Vice President | Current |
James E Flynn | Managing Partner | Current | |
Robert Contreras | Managing Director | Current |
Name | Michael A Foley | Luke Knecht | Joseph Pearlberg | James E Flynn | Robert Contreras |
---|---|---|---|---|---|
Work History | Infinity Pharmaceuticals, Sanofi, Massachusetts General Hospital, Harvard Medical School, and Harvard University | ||||
Title | Chief Executive Officer | Chief Operating Officer | Senior Vice President | Managing Partner | Managing Director |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.